Impacts

TIA is pleased to announce the outcomes of Pipeline Accelerator 2020-21 (Round 2). TIA is investing $620,000 in 18 ground-breaking therapeutic development projects listed below.

Every five years, the Australian Government consolidates and renews its policy approach to national research infrastructure (NRI) investment by engaging the research community and its

TIA is pleased to announce our latest investment in a pilot facility at BASE, UQ to produce high-quality nucleic-acid (mRNA, DNA) to support academic, translational

With the New Year comes new opportunities to learn new skills and explore new horizons. These opportunities for professional development have been offered by the

TIA held a information webinar on 2nd December 2020 to profile the expert services and advice available from the TIA consortium. Speakers from each of

Global biotech company CSL Limited will supply the Australian Government with 51 million doses of The University of Queensland’s COVID-19 vaccine candidate if it proves

Researchers at the National Biologics Facility (NBF) at The University of Queensland will benefit from a substantial funding boost for COVID-19 research. The NBF specialises

Developing early and improved diagnostic tests to lift ovarian cancer survival rates are the focus of two research projects commencing at The University of Queensland.

A process developed by University of Queensland researchers to produce larger quantities of the Hendra virus therapeutic antibody could be expanded to manufacture treatments for